• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

α2/α3亚型选择性GABAA受体正向变构调节剂KRM-II-81对大鼠疼痛抑制行为的影响:与酮咯酸和地西泮的比较

Effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam.

作者信息

Moerke Megan J, Li Guanguan, Golani Lalit K, Cook James, Negus S Stevens

机构信息

Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia.

Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.

出版信息

Behav Pharmacol. 2019 Aug;30(5):452-461. doi: 10.1097/FBP.0000000000000464.

DOI:10.1097/FBP.0000000000000464
PMID:30640180
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6610697/
Abstract

This study examined effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 in an assay of pain-related behavioral depression. Adult, male Sprague-Dawley rats responded for electrical brain stimulation in a frequency-rate intracranial self-stimulation (ICSS) procedure. Intraperitoneal injection of 1.8% lactic acid served as an acute noxious stimulus to depress ICSS. Effects of KRM-II-81 were evaluated in the absence and presence of the acid noxious stimulus. The NSAID ketorolac and the benzodiazepine diazepam were tested as comparators. Neither ketorolac nor KRM-II-81 altered ICSS in the absence of the acid noxious stimulus; however, diazepam produced facilitation consistent with its abuse liability. Ketorolac blocked acid-induced depression of ICSS, and effects of 1.0 mg/kg ketorolac lasted for at least 5 h. KRM-II-81 (1.0 mg/kg) produced significant antinociception after 30 min that dissipated by 60 min. Diazepam also attenuated acid-depressed ICSS, but only at doses that facilitated ICSS when administered alone. The lack of ketorolac or KRM-II-81 effects on ICSS in the absence of the acid noxious stimulus suggests low abuse liability for both compounds. The effectiveness of ketorolac to block acid-induced ICSS depression agrees with clinical analgesic efficacy of ketorolac. KRM-II-81 produced significant but less consistent and shorter-acting antinociception than ketorolac.

摘要

本研究在一项与疼痛相关的行为抑制试验中检测了α2/α3亚型选择性GABAA受体正向变构调节剂KRM-II-81的作用。成年雄性Sprague-Dawley大鼠在频率-速率颅内自我刺激(ICSS)程序中对脑电刺激作出反应。腹腔注射1.8%乳酸作为急性伤害性刺激以抑制ICSS。在存在和不存在酸性伤害性刺激的情况下评估KRM-II-81的作用。将非甾体抗炎药酮咯酸和苯二氮䓬类药物地西泮作为对照进行测试。在不存在酸性伤害性刺激的情况下,酮咯酸和KRM-II-81均未改变ICSS;然而,地西泮产生的促进作用与其滥用可能性一致。酮咯酸可阻断酸诱导的ICSS抑制,1.0mg/kg酮咯酸的作用持续至少5小时。KRM-II-81(1.0mg/kg)在30分钟后产生显著的抗伤害感受作用,并在60分钟时消失。地西泮也可减轻酸抑制的ICSS,但仅在单独给药时促进ICSS的剂量下有效。在不存在酸性伤害性刺激的情况下,酮咯酸或KRM-II-81对ICSS无影响,这表明这两种化合物的滥用可能性较低。酮咯酸阻断酸诱导的ICSS抑制的有效性与酮咯酸的临床镇痛疗效一致。KRM-II-81产生了显著的抗伤害感受作用,但与酮咯酸相比,其作用不太一致且持续时间较短。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/e877bb561962/nihms-1516668-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/1ea92c62047c/nihms-1516668-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/a863616ac666/nihms-1516668-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/314524386eb4/nihms-1516668-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/f2b2fd8ec26d/nihms-1516668-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/e877bb561962/nihms-1516668-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/1ea92c62047c/nihms-1516668-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/a863616ac666/nihms-1516668-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/314524386eb4/nihms-1516668-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/f2b2fd8ec26d/nihms-1516668-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6087/6610697/e877bb561962/nihms-1516668-f0005.jpg

相似文献

1
Effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam.α2/α3亚型选择性GABAA受体正向变构调节剂KRM-II-81对大鼠疼痛抑制行为的影响:与酮咯酸和地西泮的比较
Behav Pharmacol. 2019 Aug;30(5):452-461. doi: 10.1097/FBP.0000000000000464.
2
The α2,3-selective potentiator of GABA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats.α2,3-选择性 GABA 受体激动剂 KRM-II-81 可减少福尔马林和脊神经结扎诱导的大鼠痛觉相关行为。
Pharmacol Biochem Behav. 2019 May;180:22-31. doi: 10.1016/j.pbb.2019.02.013. Epub 2019 Feb 27.
3
Abuse-related effects of subtype-selective GABA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats.在大鼠颅内自我刺激试验中,亚型选择性γ-氨基丁酸(GABA)受体正向变构调节剂与滥用相关的效应。
Psychopharmacology (Berl). 2017 Jul;234(14):2091-2101. doi: 10.1007/s00213-017-4615-8. Epub 2017 Apr 1.
4
Effects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity.μ-阿片受体激动剂对雄性大鼠急性疼痛刺激和疼痛抑制行为测定的影响:μ-激动剂效能和有害刺激强度的作用
J Pharmacol Exp Ther. 2015 Feb;352(2):208-17. doi: 10.1124/jpet.114.219873. Epub 2014 Nov 18.
5
Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABA Receptor Positive Allosteric Modulator.一种新型α2/α3亚型选择性GABA受体正向变构调节剂的抗伤害感受作用
ACS Chem Neurosci. 2017 Jun 21;8(6):1305-1312. doi: 10.1021/acschemneuro.6b00447. Epub 2017 Feb 13.
6
Antinociceptive Effects of 2/3-Subtype-Selective GABA Receptor Positive Allosteric Modulators KRM-II-81 and NS16085 in Male Rats: Behavioral Specificity.2/3 型 GABA 受体正变构调节剂 KRM-II-81 和 NS16085 在雄性大鼠中的抗伤害作用:行为特异性。
J Pharmacol Exp Ther. 2024 Nov 19;391(3):389-398. doi: 10.1124/jpet.123.002070.
7
Effects of nicotinic acetylcholine receptor agonists in assays of acute pain-stimulated and pain-depressed behaviors in rats.烟碱型乙酰胆碱受体激动剂对大鼠急性疼痛刺激和疼痛抑制行为测定的影响。
J Pharmacol Exp Ther. 2015 Nov;355(2):341-50. doi: 10.1124/jpet.115.226803.
8
Effects of repeated treatment with monoamine-transporter-inhibitor antidepressants on pain-related depression of intracranial self-stimulation in rats.反复使用单胺转运体抑制剂抗抑郁药对大鼠颅内自我刺激相关疼痛抑郁的影响。
Psychopharmacology (Berl). 2020 Jul;237(7):2201-2212. doi: 10.1007/s00213-020-05530-y. Epub 2020 May 8.
9
Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior.疼痛与镇痛相关操作对大鼠颅内自我刺激的影响:对疼痛抑制行为的进一步研究。
Pain. 2009 Jul;144(1-2):170-7. doi: 10.1016/j.pain.2009.04.010. Epub 2009 May 10.
10
Dissociable effects of the cannabinoid receptor agonists Δ9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats.大麻素受体激动剂 Δ9-四氢大麻酚和 CP55940 对大鼠疼痛刺激与疼痛抑制行为的分离作用。
J Pharmacol Exp Ther. 2012 Nov;343(2):389-400. doi: 10.1124/jpet.112.197780. Epub 2012 Aug 14.

引用本文的文献

1
Antinociceptive Effects of 2/3-Subtype-Selective GABA Receptor Positive Allosteric Modulators KRM-II-81 and NS16085 in Male Rats: Behavioral Specificity.2/3 型 GABA 受体正变构调节剂 KRM-II-81 和 NS16085 在雄性大鼠中的抗伤害作用:行为特异性。
J Pharmacol Exp Ther. 2024 Nov 19;391(3):389-398. doi: 10.1124/jpet.123.002070.
2
Identification of New Antiseizure Medication Candidates in Preclinical Animal Studies.在临床前动物研究中鉴定新型抗癫痫药物候选物。
Int J Mol Sci. 2023 Aug 24;24(17):13143. doi: 10.3390/ijms241713143.
3
Structural Analogs of the GABAkine KRM-II-81 Are Orally Bioavailable Anticonvulsants without Sedation.

本文引用的文献

1
Helping to End Addiction Over the Long-term: The Research Plan for the NIH HEAL Initiative.助力长期戒除成瘾:美国国立卫生研究院治愈计划研究方案
JAMA. 2018 Jul 10;320(2):129-130. doi: 10.1001/jama.2018.8826.
2
Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABA receptors: Improved bioavailability enhances anticonvulsant efficacy.乙基 8-乙炔基-6-(吡啶-2-基)-4H-苯并[f]咪唑[1,5-a][1,4]二氮杂*-3-羧酸酯(HZ-166)的生物等排体作为新型的α2,3 选择性 GABA 受体增效剂:生物利用度的提高增强了抗惊厥作用。
Neuropharmacology. 2018 Jul 15;137:332-343. doi: 10.1016/j.neuropharm.2018.05.006. Epub 2018 May 3.
3
GABAkine KRM-II-81 的结构类似物是具有口服生物利用度的抗惊厥药物,无镇静作用。
J Pharmacol Exp Ther. 2023 Apr;385(1):50-61. doi: 10.1124/jpet.122.001362. Epub 2023 Feb 6.
4
GABA receptor subtypes and benzodiazepine use, misuse, and abuse.γ-氨基丁酸(GABA)受体亚型与苯二氮䓬类药物的使用、误用及滥用
Front Psychiatry. 2023 Jan 12;13:1060949. doi: 10.3389/fpsyt.2022.1060949. eCollection 2022.
5
Lack of effect of the nociceptin opioid peptide agonist Ro 64-6198 on pain-depressed behavior and heroin choice in rats.阿片肽类激动剂 Ro 64-6198 对痛觉缺失行为和大鼠海洛因选择无影响。
Drug Alcohol Depend. 2022 Feb 1;231:109255. doi: 10.1016/j.drugalcdep.2021.109255. Epub 2021 Dec 30.
6
GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABA receptors.GABAkines- GABA 受体正向变构调节剂的发现、开发和商业化进展。
Pharmacol Ther. 2022 Jun;234:108035. doi: 10.1016/j.pharmthera.2021.108035. Epub 2021 Nov 16.
7
Design, synthesis and characterization of novel gamma‑aminobutyric acid type A receptor ligands.新型γ-氨基丁酸A型受体配体的设计、合成与表征
ARKIVOC. 2020;2020(Pt 7):242-256. doi: 10.24820/ark.5550190.p011.398. Epub 2020 Dec 2.
8
Effects of repeated treatment with monoamine-transporter-inhibitor antidepressants on pain-related depression of intracranial self-stimulation in rats.反复使用单胺转运体抑制剂抗抑郁药对大鼠颅内自我刺激相关疼痛抑郁的影响。
Psychopharmacology (Berl). 2020 Jul;237(7):2201-2212. doi: 10.1007/s00213-020-05530-y. Epub 2020 May 8.
9
The Positive Allosteric Modulator of 2/3-Containing GABA Receptors, KRM-II-81, Is Active in Pharmaco-Resistant Models of Epilepsy and Reduces Hyperexcitability after Traumatic Brain Injury.含 2/3 型 GABA 受体的正变构调节剂 KRM-II-81 在癫痫耐药模型中有效,并降低创伤性脑损伤后的过度兴奋。
J Pharmacol Exp Ther. 2020 Jan;372(1):83-94. doi: 10.1124/jpet.119.260968. Epub 2019 Nov 6.
10
The α2,3-selective potentiator of GABA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats.α2,3-选择性 GABA 受体激动剂 KRM-II-81 可减少福尔马林和脊神经结扎诱导的大鼠痛觉相关行为。
Pharmacol Biochem Behav. 2019 May;180:22-31. doi: 10.1016/j.pbb.2019.02.013. Epub 2019 Feb 27.
Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability.
新型氘代配体的设计与合成,对 γ-氨基丁酸 A 型受体(GABAR)α6 亚型具有功能选择性,代谢稳定性提高,生物利用度增强。
J Med Chem. 2018 Mar 22;61(6):2422-2446. doi: 10.1021/acs.jmedchem.7b01664. Epub 2018 Mar 6.
4
The Role of Science in Addressing the Opioid Crisis.科学在应对阿片类药物危机中的作用。
N Engl J Med. 2017 Jul 27;377(4):391-394. doi: 10.1056/NEJMsr1706626. Epub 2017 May 31.
5
Abuse-related effects of subtype-selective GABA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats.在大鼠颅内自我刺激试验中,亚型选择性γ-氨基丁酸(GABA)受体正向变构调节剂与滥用相关的效应。
Psychopharmacology (Berl). 2017 Jul;234(14):2091-2101. doi: 10.1007/s00213-017-4615-8. Epub 2017 Apr 1.
6
Pharmacological and antihyperalgesic properties of the novel α2/3 preferring GABA receptor ligand MP-III-024.新型α2/3选择性GABA受体配体MP-III-024的药理学及抗痛觉过敏特性
Brain Res Bull. 2017 May;131:62-69. doi: 10.1016/j.brainresbull.2017.03.001. Epub 2017 Mar 4.
7
Diazepam Is No Better Than Placebo When Added to Naproxen for Acute Low Back Pain.地西泮与萘普生联用治疗急性下腰痛时并不比安慰剂效果更好。
Ann Emerg Med. 2017 Aug;70(2):169-176.e1. doi: 10.1016/j.annemergmed.2016.10.002. Epub 2017 Feb 7.
8
Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABA Receptor Positive Allosteric Modulator.一种新型α2/α3亚型选择性GABA受体正向变构调节剂的抗伤害感受作用
ACS Chem Neurosci. 2017 Jun 21;8(6):1305-1312. doi: 10.1021/acschemneuro.6b00447. Epub 2017 Feb 13.
9
Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy.一种新型γ-氨基丁酸A型(GABA)受体配体的合成与表征,该配体兼具出色的代谢稳定性、药代动力学和抗焦虑功效。
J Med Chem. 2016 Dec 8;59(23):10800-10806. doi: 10.1021/acs.jmedchem.6b01332. Epub 2016 Nov 28.
10
The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia.氯巴占代谢物N-去甲基氯巴占是一种优先作用于α2的苯二氮䓬类药物,其抗痛觉过敏的治疗窗有所改善。
Neuropharmacology. 2016 Oct;109:366-375. doi: 10.1016/j.neuropharm.2016.07.004. Epub 2016 Jul 5.